AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27254026 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (Cisplatin and 5-fluorouracil with concurrent radiotherapy 40 Gy)
Number of subjects: 31
Study 24459063 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 39
Study 24459063 — intervention group
Group type: COMPARATOR
Intervention: glimepiride
Number of subjects: 39
Study 22781570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 427
Study 20453734 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 63
Study 17627724 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment protocol (ITP) with sildenafil and cognitive-behavior sex therapy (CBST) for the first 4 weeks, followed by continued ITP for the last 4 weeks
Number of subjects: 53
Study 17627724 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil alone for the first 4 weeks, followed by addition of CBST for the last 4 weeks
Number of subjects: 53
Study 17627724 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment protocol (ITP) with sildenafil and cognitive-behavior sex therapy (CBST) for the entire 8 weeks
Number of subjects: 53
Study 15675894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1 g three times a day for 2 weeks)
Number of subjects: 17
Study 15675894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 15675894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 17
Study 11849797 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (300 mg/m(2) administered 15-30 min before RT for 6-7.5 weeks)
Number of subjects: 50
Study 11849797 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy and carboplatin (90 mg/m(2) infusion once per week before RT)
Number of subjects: 50
Study 9630382 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low energy formula diet (2 MJ/d for 8 weeks)
Number of subjects: 36
Study 9630382 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy conventional diet (5 MJ/d for 17 weeks)
Number of subjects: 36
Study 9630382 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet ad libitum (n=16)
Number of subjects: 36
Study 9630382 — intervention group
Group type: COMPARATOR
Intervention: Energy-restricted diet (n=20)
Number of subjects: 36
Study 7739031 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect range restriction in high-risk studies
Number of subjects: 0
Study 7739031 — intervention group
Group type: EXPERIMENTAL
Intervention: Range restriction approach
Number of subjects: 0
Study 2971268 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline/benzylpenicillin procaine (DC + BP)
Number of subjects: 64
Study 2971268 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 64
Study 29627608 — intervention group
Group type: EXPERIMENTAL
Intervention: Semicircular (SC) arm stroke technique
Number of subjects: 18
Study 29627608 — intervention group
Group type: COMPARATOR
Intervention: Pump (P) arm stroke technique
Number of subjects: 18
Study 25879690 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (100 g/day) + placebo capsule
Number of subjects: 70
Study 25879690 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsule + conventional yogurt (100 g/day)
Number of subjects: 70
Study 25879690 — intervention group
Group type: COMPARATOR
Intervention: Conventional yogurt (100 g/day) + placebo capsule
Number of subjects: 70
Study 23813627 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline C-reactive protein (CRP) levels
Number of subjects: 96
Study 23813627 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP >1 mg/L
Number of subjects: 96
Study 23813627 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex bifurcation strategy
Number of subjects: 96
Study 23813627 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural myocardial necrosis
Number of subjects: 96
Study 22241764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 μg
Number of subjects: 602
Study 22241764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 50 μg
Number of subjects: 602
Study 22241764 — intervention group
Group type: COMPARATOR
Intervention: Vilanterol (VI) 3, 6.25, 12.5, 25, or 50 μg
Number of subjects: 602
Study 22241764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 20308695 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate sports drink (CHO)
Number of subjects: 23
Study 20308695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 23
Study 18494633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chariker‐Jeter gauze‐based negative pressure systems (V1STA, Versatile‐1 and EZ‐Care; Smith & Nephew, Inc.) at -80 mmHg
Number of subjects: 30
Study 15981670 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-tract reconstruction group
Number of subjects: 19
Study 15981670 — intervention group
Group type: EXPERIMENTAL
Intervention: Large residual stomach
Number of subjects: 19
Study 15981670 — intervention group
Group type: COMPARATOR
Intervention: Preoperative control group
Number of subjects: 19
Study 15213209 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes (weight loss and increased physical activity)
Number of subjects: 110
Study 15213209 — intervention group
Group type: COMPARATOR
Intervention: General information about healthy food choices and exercise (Control)
Number of subjects: 110
Study 10670838 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (ISS >= 27)
Number of subjects: 43
Study 9493699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of isradipine 2.5 mg plus spirapril 3 mg
Number of subjects: 405
Study 9493699 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg
Number of subjects: 405
Study 9493699 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg
Number of subjects: 405
Study 9493699 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg
Number of subjects: 405
Study 9493699 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg
Number of subjects: 405
Study 9493699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 7687157 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 23% saturated hypertonic saline
Number of subjects: 10
Study 7687157 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of 7.5% hypertonic saline
Number of subjects: 10
Study 7687157 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of 7.5% saline with 6% dextran 70
Number of subjects: 10
Study 3599565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3599565 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 16
Study 3599565 — intervention group
Group type: EXPERIMENTAL
Intervention: Amobarbital 80 mg
Number of subjects: 16
Study 3599565 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 15 mg
Number of subjects: 16
Study 2660556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, 1 g twice daily
Number of subjects: 88
Study 2660556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 27781419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet form of mycophenolate mofetil (500 mg)
Number of subjects: 156
Study 27781419 — intervention group
Group type: COMPARATOR
Intervention: Capsule form of mycophenolate mofetil (250 mg)
Number of subjects: 156
Study 27781419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet form of mycophenolate mofetil
Number of subjects: 156
Study 27781419 — intervention group
Group type: COMPARATOR
Intervention: Capsule form of mycophenolate mofetil
Number of subjects: 156
Study 29522863 — intervention group
Group type: COMPARATOR
Intervention: Limited CCRT intervention arm (malaria children)
Number of subjects: 300
Study 29522863 — intervention group
Group type: COMPARATOR
Intervention: Full CCRT (non-malaria children)
Number of subjects: 300
Study 29297902 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 4572
Study 29297902 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX
Number of subjects: 4572
Study 29297902 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus nab-paclitaxel
Number of subjects: 4572
Study 29297902 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine alone
Number of subjects: 4572
Study 26200980 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-7288 (1 mg, 4 mg, 8 mg, 12 mg, or 16 mg per kilogram of body weight)
Number of subjects: 40
Study 26200980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23583478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (teachers trained in nutrition)
Number of subjects: 464
Study 23583478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 464
Study 21661445 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (10mg) with 50 mL of water
Number of subjects: 6
Study 21661445 — intervention group
Group type: COMPARATOR
Intervention: 50 mL of water alone
Number of subjects: 6
Study 18988664 — intervention group
Group type: EXPERIMENTAL
Intervention: Early progressive eccentric exercise
Number of subjects: 40
Study 18988664 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 40
Study 16712431 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid blockade (8 mg naloxone i.v.)
Number of subjects: 115
Study 16712431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 15165089 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cisplatin (20mg/m2 cisplatin 1 h before radiotherapy, given on days 1-5 of the second and sixth treatment weeks)
Number of subjects: 176
Study 15165089 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (64 Gy for 6-7 weeks, 2 Gy given 32 times, in five fractions a week)
Number of subjects: 176
Study 15165089 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cisplatin
Number of subjects: 176
Study 15165089 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 176
Study 11712351 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0 micrograms.kg‐1
Number of subjects: 55
Study 11712351 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms.kg‐1
Number of subjects: 55
Study 11712351 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3 micrograms.kg‐1
Number of subjects: 55
Study 11712351 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 4 micrograms.kg‐1
Number of subjects: 55
Study 11712351 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (any dose)
Number of subjects: 55
Study 9217590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9217590 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg i.v. cocaine
Number of subjects: 12
Study 9217590 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg i.v. cocaine
Number of subjects: 12
Study 8353352 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac plexus block (30 mL of 0.25% bupivacaine)
Number of subjects: 32
Study 8353352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 mL of normal saline)
Number of subjects: 32
Study 3301504 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 450 mg or 900 mg daily
Number of subjects: 13
Study 3301504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 28797704 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian New Moves program (NMP)
Number of subjects: 270
Study 28797704 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 270
Study 27160639 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg and titrated to 300 mg)
Number of subjects: 218
Study 27160639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 27160639 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 218
Study 25612082 — intervention group
Group type: EXPERIMENTAL
Intervention: Skimmed milk, whey, casein (all milk-based drinks 35g protein/L)
Number of subjects: 193
Study 25612082 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 193
Study 25612082 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 193
Study 25612082 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 193
Study 25612082 — intervention group
Group type: COMPARATOR
Intervention: Pre-test control group
Number of subjects: 193
Study 23786940 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg/Lercanidipine 10 mg
Number of subjects: 181
Study 23786940 — intervention group
Group type: COMPARATOR
Intervention: Benazepril 10 mg
Number of subjects: 181
Study 20442614 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage intervention (10 to 15 minutes daily starting at 15 days old)
Number of subjects: 100
Study 20442614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 100
Study 20442614 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage intervention
Number of subjects: 100
Study 18822094 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 18822094 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30
Study 16723051 — intervention group
Group type: EXPERIMENTAL
Intervention: desflurane-remifentanil
Number of subjects: 231
Study 16723051 — intervention group
Group type: COMPARATOR
Intervention: sevoflurane-remifentanil
Number of subjects: 231
Study 12797850 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system
Number of subjects: 0
Study 12797850 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative laparoscopic surgery
Number of subjects: 0
Study 12797850 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial ablation
Number of subjects: 0
Study 12797850 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of submucous fibroids via hysteroscope
Number of subjects: 0
Study 12797850 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern medical therapies
Number of subjects: 0
Study 12797850 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgical therapies
Number of subjects: 0
Study 11317593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lippia javanica alcohol extract
Number of subjects: 3
Study 11317593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cymbopogon excavatus alcohol extract
Number of subjects: 3
Study 11317593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelargonium reniforme alcohol extract
Number of subjects: 3
Study 11317593 — intervention group
Group type: COMPARATOR
Intervention: Alcohol control
Number of subjects: 3
Study 8652316 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (bolus dose 2 mg, lockout time 10 min)
Number of subjects: 40
Study 8652316 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (bolus dose 20 mg, lockout time 10 min)
Number of subjects: 40
Study 8652316 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and Pethidine
Number of subjects: 40
Study 8652316 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 40
Study 8652316 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 40
Study 1907317 — intervention group
Group type: COMPARATOR
Intervention: DTP vaccine
Number of subjects: 497
Study 1907317 — intervention group
Group type: EXPERIMENTAL
Intervention: APDT vaccine
Number of subjects: 497
Study 6576622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabur‐Test 5000
Number of subjects: 0
Study 6576622 — intervention group
Group type: COMPARATOR
Intervention: Clinitest method
Number of subjects: 0
Study 30802204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol 1.02 g (2 × 510 mg)
Number of subjects: 293
Study 30802204 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose 1.0 g (10 × 100 mg)
Number of subjects: 293
Study 29661267 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic (computer-based) START triage
Number of subjects: 6
Study 29661267 — intervention group
Group type: COMPARATOR
Intervention: Manual (paper-based) START triage
Number of subjects: 6
Study 26515276 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored newsletters and motivational calls from a peer counselor
Number of subjects: 712
Study 26515276 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 712
Study 23786544 — intervention group
Group type: EXPERIMENTAL
Intervention: LI4 group (n = 40) - bilateral LI4 acupuncture points stimulated using transcutaneous electrical nerve stimulation‐acupuncture pen.
Number of subjects: 120
Study 23786544 — intervention group
Group type: EXPERIMENTAL
Intervention: SP6 group (n = 40) - acupuncture points of both legs stimulated using the same procedure as LI4 group.
Number of subjects: 120
Study 23786544 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 40) - no stimulation.
Number of subjects: 120
Study 22581048 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic aspherical intraocular lens (Polytech Y10AS)
Number of subjects: 100
Study 22581048 — intervention group
Group type: COMPARATOR
Intervention: Hydrophobic acrylic spherical intraocular lens (Hoya PC-60R)
Number of subjects: 100
Study 20354684 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone for 24 weeks
Number of subjects: 111
Study 20354684 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 111
Study 20354684 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 111
Study 20354684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 20354684 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone and Placebo
Number of subjects: 111
Study 19102141 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotatory manual reduction with forceps holder and retrograde percutaneous pinning transfixation
Number of subjects: 201
Study 19102141 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation with Kirschner pin
Number of subjects: 201
Study 15968307 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-dependent intermittent catheterization (VDIC)
Number of subjects: 24
Study 15968307 — intervention group
Group type: COMPARATOR
Intervention: Time-dependent intermittent catheterization (TDIC)
Number of subjects: 24
Study 12362928 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol Transdermal System (Mylan Pharmaceuticals, Inc.)
Number of subjects: 42
Study 12362928 — intervention group
Group type: COMPARATOR
Intervention: Climara (Berlex Laboratories, Inc.)
Number of subjects: 42
Study 10434162 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg kg‐1 and suxamethonium 1.5 mg kg‐1 (group TS)
Number of subjects: 90
Study 10434162 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 5 Vol.% (group H)
Number of subjects: 90
Study 10434162 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1 and propofol 3 mg kg‐1 (group PA)
Number of subjects: 90
Study 7598289 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1%
Number of subjects: 55
Study 7598289 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.5%
Number of subjects: 55
Study 7598289 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (1.5 mL bupivacaine 0.75% with fentanyl 10 micrograms)
Number of subjects: 55
Study 2240678 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic segmental epidural anesthesia with bupivacaine (4.2 ml, 0.75%)
Number of subjects: 53
Study 2240678 — intervention group
Group type: EXPERIMENTAL
Intervention: Midthoracic epidural anesthesia with bupivacaine
Number of subjects: 53
Study 2240678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural anesthesia with bupivacaine
Number of subjects: 53
Study 2240678 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) control for high thoracic segmental epidural anesthesia
Number of subjects: 53
Study 2240678 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) control for midthoracic and lumbar epidural anesthesia
Number of subjects: 53
Study 773498 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 300 mg daily
Number of subjects: 20
Study 773498 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 600 mg daily
Number of subjects: 20
Study 773498 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20
Study 773498 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 30553078 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP-R intervention (full access to web-based survivorship care plan with text message support)
Number of subjects: 318
Study 30553078 — intervention group
Group type: COMPARATOR
Intervention: Attention control (access to a list of online resources)
Number of subjects: 318
Study 30553078 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare provider outcomes
Number of subjects: 318
Study 26856929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixantrone
Number of subjects: 0
Study 26856929 — intervention group
Group type: COMPARATOR
Intervention: Current Clinical Practice (CCP)
Number of subjects: 0
Study 24700493 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration (SR-WBV) intervention at 6 Hz, noise level 4
Number of subjects: 24
Study 24081777 — intervention group
Group type: EXPERIMENTAL
Intervention: FFRCT
Number of subjects: 252
Study 24081777 — intervention group
Group type: COMPARATOR
Intervention: CT stenosis
Number of subjects: 252
Study 20231842 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (1 × 10(10) CFU of Lactobacillus rhamnosus GG, ATCC 53103)
Number of subjects: 159
Study 20231842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 18421406 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction programme (low-calorie diet and exercise)
Number of subjects: 64
Study 15902724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu capsule
Number of subjects: 216
Study 15902724 — intervention group
Group type: COMPARATOR
Intervention: Heluoshugan capsule
Number of subjects: 216